search
Back to results

Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques (SAKOS)

Primary Purpose

Spinal Fractures, Vertebral Compression Fractures, Back Injuries

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Vertebral fracture surgery SpineJack®
Balloon Kyphoplasty
Sponsored by
Vexim SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Fractures

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or Female with at least 50 years of age
  2. 1 painful VCF which at least meet all following criteria:

    • Fracture due to diagnosed or presumed underlying osteoporosis
    • VCF between T7 and L3
    • Fracture age <3 months
    • VCF shows loss of height in the anterior, mid or posterior third of the VB from estimated pre-fracture configuration of at least 15% but not more than 40% based on X-Ray at baseline
    • The Index fracture is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI)
  3. Patient has failed conservative medical therapy, defined as either having a VAS back pain score of ≥50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of ≥70mm at 2 weeks after initiation of fracture care
  4. Investigator believes target VB is suitable for SpineJack procedure and Balloon kyphoplasty (e.g., appropriate pedicle diameter) assessed on CT scan pre op
  5. Patient has an Oswestry Disability Index (ODI) score of ≥ 30/100
  6. Patient is mentally capable and willing to sign a study specific informed consent as documentation of the informed consent process prior to any study procedures
  7. The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments.

Exclusion Criteria:

  1. Target VCF due to underlying or suspected tumor
  2. Target VCF due to high-energy trauma
  3. Target VCF is diagnosed as an osteonecrotic fracture
  4. Segmental kyphosis of target VB of >30°
  5. Any prior surgical treatment for a vertebral body compression fracture or other surgical procedure on target VB or adjacent level
  6. The patient has uncontrolled diabetes
  7. Pre-existing or clinically unstable neurologic deficit
  8. The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
  9. Any physical exam evidence of myelopathy or radiculopathy
  10. The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
  11. Patient not able to walk without assistance prior to fracture
  12. Any radiographic evidence of pedicle fracture visible on CT scan pre op
  13. Spondylolisthesis >Grade 1 at target VB
  14. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
  15. A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000)
  16. Pain due to any other condition that requires daily narcotic medication
  17. Disabling back pain due to causes other than acute fracture
  18. History of intolerance or allergic reaction to titanium or acrylic compounds
  19. Active systemic or local infection at baseline
  20. Body mass index >40
  21. Severe cardiopulmonary deficiencies
  22. Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery including but not limited to patients with contraindications for general anesthesia (surgeon expertise)
  23. Any evidence of alcohol or drug abuse
  24. The patient has uncontrolled psychiatric illness or severe dementia
  25. The patient is currently on anti-cancer therapy or anti-HIV therapy
  26. Patient's life expectancy is less than the study duration or undergoing palliative care
  27. Participating in any other investigational study
  28. The patient is on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months)
  29. The patient is known to be involved in medical litigation including Workmen's Compensation
  30. Patient with contraindication for MRI
  31. The patient is pregnant or considering getting pregnant during study participation.

Sites / Locations

  • Hôpital Jean Minjoz Service Neurochirurgie
  • Centre Hospitalier La Cavale Blanche
  • CHU La Timone
  • Hôpital Nord
  • CHU Hôtel Dieu Service Neuro traumatologie
  • Klinik und Poliklinik fur Orthopädie Universitatsklinikum
  • Loretto-Krankenhaus Freiburg
  • Krankenhaus NEUWERK Sankt Augustinus kliniken
  • Ospedale SS Trinita ASL8
  • Hospital Universitario Marques de Valdecilla
  • Hospital Clinico Universitario de Valladolid,
  • HFR Fribourg - Hôpital cantonal
  • Clinique Bois-Cerf

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

SpineJack® system

Balloon Kyphoplasty

Arm Description

VCF treatment system Vertebral fracture surgery

VCF treatment system Vertebral fracture surgery

Outcomes

Primary Outcome Measures

Proportion of Participants With Study Success
The primary composite endpoint defines a successful subject if the following components are satisfied (safety and effectiveness): Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by > 20 mm) AND, Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND, Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation.

Secondary Outcome Measures

Full Information

First Posted
May 27, 2015
Last Updated
February 21, 2019
Sponsor
Vexim SA
Collaborators
ACES Ing.-GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT02461810
Brief Title
Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques
Acronym
SAKOS
Official Title
A Prospective, Multicenter, Randomized, Comparative Clinical Study to Compare the Safety and Effectiveness of Two Vertebral Compression Fracture (VCF) Reduction Techniques: the SpineJack® and the KyphX Xpander® Inflatable Bone Tamp
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
February 20, 2018 (Actual)
Study Completion Date
February 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vexim SA
Collaborators
ACES Ing.-GmbH

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare the safety and effectiveness of the SpineJack® with the Kyphx Xpander® Inflatable Bone Tamp and support a non-inferiority finding for the use of SpineJack® VCF treatment system versus Balloon Kyphoplasty.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Fractures, Vertebral Compression Fractures, Back Injuries, Osteoporosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
152 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SpineJack® system
Arm Type
Experimental
Arm Description
VCF treatment system Vertebral fracture surgery
Arm Title
Balloon Kyphoplasty
Arm Type
Active Comparator
Arm Description
VCF treatment system Vertebral fracture surgery
Intervention Type
Device
Intervention Name(s)
Vertebral fracture surgery SpineJack®
Intervention Description
Vertebral augmentation for one osteoporotic vertebral compression fracture
Intervention Type
Procedure
Intervention Name(s)
Balloon Kyphoplasty
Primary Outcome Measure Information:
Title
Proportion of Participants With Study Success
Description
The primary composite endpoint defines a successful subject if the following components are satisfied (safety and effectiveness): Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by > 20 mm) AND, Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND, Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation.
Time Frame
12 month post-op

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or Female with at least 50 years of age 1 painful VCF which at least meet all following criteria: Fracture due to diagnosed or presumed underlying osteoporosis VCF between T7 and L3 Fracture age <3 months VCF shows loss of height in the anterior, mid or posterior third of the VB from estimated pre-fracture configuration of at least 15% but not more than 40% based on X-Ray at baseline The Index fracture is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI) Patient has failed conservative medical therapy, defined as either having a VAS back pain score of ≥50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of ≥70mm at 2 weeks after initiation of fracture care Investigator believes target VB is suitable for SpineJack procedure and Balloon kyphoplasty (e.g., appropriate pedicle diameter) assessed on CT scan pre op Patient has an Oswestry Disability Index (ODI) score of ≥ 30/100 Patient is mentally capable and willing to sign a study specific informed consent as documentation of the informed consent process prior to any study procedures The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments. Exclusion Criteria: Target VCF due to underlying or suspected tumor Target VCF due to high-energy trauma Target VCF is diagnosed as an osteonecrotic fracture Segmental kyphosis of target VB of >30° Any prior surgical treatment for a vertebral body compression fracture or other surgical procedure on target VB or adjacent level The patient has uncontrolled diabetes Pre-existing or clinically unstable neurologic deficit The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated Any physical exam evidence of myelopathy or radiculopathy The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis) Patient not able to walk without assistance prior to fracture Any radiographic evidence of pedicle fracture visible on CT scan pre op Spondylolisthesis >Grade 1 at target VB Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.) A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000) Pain due to any other condition that requires daily narcotic medication Disabling back pain due to causes other than acute fracture History of intolerance or allergic reaction to titanium or acrylic compounds Active systemic or local infection at baseline Body mass index >40 Severe cardiopulmonary deficiencies Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery including but not limited to patients with contraindications for general anesthesia (surgeon expertise) Any evidence of alcohol or drug abuse The patient has uncontrolled psychiatric illness or severe dementia The patient is currently on anti-cancer therapy or anti-HIV therapy Patient's life expectancy is less than the study duration or undergoing palliative care Participating in any other investigational study The patient is on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months) The patient is known to be involved in medical litigation including Workmen's Compensation Patient with contraindication for MRI The patient is pregnant or considering getting pregnant during study participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre HONTAS, Director Clinical Affairs
Organizational Affiliation
Vexim SA
Official's Role
Study Director
Facility Information:
Facility Name
Hôpital Jean Minjoz Service Neurochirurgie
City
Besancon
Country
France
Facility Name
Centre Hospitalier La Cavale Blanche
City
Brest
Country
France
Facility Name
CHU La Timone
City
Marseille
Country
France
Facility Name
Hôpital Nord
City
Marseille
Country
France
Facility Name
CHU Hôtel Dieu Service Neuro traumatologie
City
Nantes
Country
France
Facility Name
Klinik und Poliklinik fur Orthopädie Universitatsklinikum
City
Bonn
Country
Germany
Facility Name
Loretto-Krankenhaus Freiburg
City
Freiburg
Country
Germany
Facility Name
Krankenhaus NEUWERK Sankt Augustinus kliniken
City
Monchengladbach
Country
Germany
Facility Name
Ospedale SS Trinita ASL8
City
Cagliari
Country
Italy
Facility Name
Hospital Universitario Marques de Valdecilla
City
Santander
Country
Spain
Facility Name
Hospital Clinico Universitario de Valladolid,
City
Valladolid
Country
Spain
Facility Name
HFR Fribourg - Hôpital cantonal
City
Fribourg
Country
Switzerland
Facility Name
Clinique Bois-Cerf
City
Lausanne
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques

We'll reach out to this number within 24 hrs